Posts

Novartis CEO on $12B Avidity Deal: 'Could Have Been Twice as Big'

on

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

on

Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal

on

Lilly Expands Gene Therapy Presence with Acquisition of Adverum Biotechnologies

on

Alkermes Acquires Avadel Pharmaceuticals for $2.1B, Gaining Sleep Drug LUMRYZ and Setting Strategic Evolution

on

Sanofi’s efdoralprin alfa (INBRX-101) achieves all endpoints in Phase 2 alpha-1 antitrypsin deficiency (AATD) trial

on

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

on

BioCryst Snaps Up Fellow Angioedema Player Astria for $700M

on

Bristol Myers Squibb Enters In Vivo CAR-T Field with $1.5B Acquisition of Orbital Therapeutics

on

Halozyme to Acquire Elektrofi for $750 Million, Expanding Drug Delivery Capabilities

on

Tourmaline Attracted Bidding War Before $1.4B Acquisition by Novartis

on

Genmab CEO on the $8B Acquisition of Merus: Strategy Behind the 'Very Fair' Deal and Plans to Polish a Rough Diamond

on

Celltrion Acquires Eli Lilly’s New Jersey Manufacturing Site for $330 Million

on

Pfizer Acquires Metsera to Compete with Zepbound in Obesity Market

on

Roche Acquires 89bio with $2.4 Billion Buyout to Enter FGF21 MASH Therapeutics Space

on

Genmab Abandons ADC Asset Acquired in $1.8B ProfoundBio Deal

on

CSL Commits $117M for Option to Acquire VarmX and Advance Novel Blood Clotting Therapy to Market

on

Novartis Acquires Tourmaline Bio for $1.4B to Bolster Cardiovascular Pipeline with Promising Phase 2 Drug

on

Servier Supercharges Neuro Pipeline with $450M Deal for Fragile X Syndrome Candidate

on

AbbVie Buys Gilgamesh's Psychedelic Drug Bretisilocin for $1.2B

on